Novabridge Biosciences (NBP) Stock Price, News & Analysis

Novabridge Biosciences logo
$0.82 +0.03 (+3.89%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.84 +0.01 (+1.67%)
As of 07:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Novabridge Biosciences Stock (NASDAQ:NBP)

Advanced

Key Stats

Today's Range
$0.75
▼
$0.83
50-Day Range
$0.79
▼
$1.70
52-Week Range
$0.75
▼
$5.19
Volume
858,490 shs
Average Volume
550,099 shs
Market Capitalization
$95.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Hold

Company Overview

Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival.

The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets. These products remain in clinical development and are not necessarily approved for commercial use.

Novabridge Biosciences was founded in 2016 and historically maintained operations and development activities in both China and the United States. The company has since emphasized a more globally oriented, U.S.-focused development strategy while continuing to advance selected oncology programs through clinical studies and potential strategic partnerships. Dr. Joan Shen, a biopharmaceutical executive and physician, is the company’s founder and has served in senior leadership roles.

AI Generated. May Contain Errors.

Novabridge Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

NBP MarketRank™: 
2.8767671379 of 5 stars

Novabridge Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 465th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novabridge Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Novabridge Biosciences has a consensus price target of $9.00, representing about 994.5% upside from its current price of $0.82.

  • Amount of Analyst Coverage

    Novabridge Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Novabridge Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Novabridge Biosciences are expected to decrease in the coming year, from ($0.54) to ($0.99) per share.

  • Price to Book Value per Share Ratio

    Novabridge Biosciences has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.96% of the float of Novabridge Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Novabridge Biosciences has a short interest ratio ("days to cover") of 6.89.
  • Change versus previous month

    Short interest in Novabridge Biosciences has recently decreased by 3.29%, indicating that investor sentiment is improving.
  • Dividend Yield

    Novabridge Biosciences does not currently pay a dividend.

  • Dividend Growth

    Novabridge Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Novabridge Biosciences has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Novabridge Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $88,325.00 in company stock.

  • Percentage Held by Insiders

    22.10% of the stock of Novabridge Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    38.38% of the stock of Novabridge Biosciences is held by institutions.

  • Read more about Novabridge Biosciences' insider trading history.
Receive NBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novabridge Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBP Stock News Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Brokers Offer Predictions for NBP FY2026 Earnings
See More Headlines

NBP Stock Analysis - Frequently Asked Questions

Novabridge Biosciences' stock was trading at $3.70 on February 6, 2026. Since then, NBP shares have decreased by 77.8% and is now trading at $0.8223.

Novabridge Biosciences (NASDAQ:NBP) posted its quarterly earnings results on Thursday, August, 20th. The company reported ($0.16) EPS for the quarter.

Top institutional investors of Novabridge Biosciences include Marshall Wace LLP (0.63%), State Street Corp (0.27%) and Goldman Sachs Group Inc. (0.11%). Insiders that own company stock include Cong Claire Xu, Sean Wuxiong Cao, Mark Arnold Hagler and Phillip Andrew Dennis.
View institutional ownership trends
.

Shares of NBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/20/2026
Today
11/17/2026
9th Annual Evercore ISI HealthCONx Conference
11/30/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NBP
CIK
1778016
Fax
N/A
Employees
30
Year Founded
2016

Price Target and Rating

High Price Target
$9.00
Low Price Target
$9.00
Potential Upside/Downside
+994.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.64
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$3.89 million
Price / Sales
24.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.00 per share
Price / Book
0.41

Miscellaneous

Outstanding Shares
116,000,000
Free Float
90,363,000
Market Cap
$95.39 million
Optionable
Optionable
Beta
1.70

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:NBP) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners